en Hematology Hematology Original Article Original Article <p dir="ltr" style="text-align: justify;"><span style="font-family: times new roman;"><strong><em><span style="color: blue; font-size: 10pt;">Background: </span></em></strong><span style="font-size: 10pt;">BCL-2 is the most important anti-apoptotic regulator and Bax is a pro-apoptotic protein. The status of these parameters or the ration of BCL-2 to BAX is important in malignant cell fate as well as normal cells.</span></span></p> <p dir="ltr" style="text-align: justify;"><span style="font-family: times new roman;"><strong><em><span style="color: blue; font-size: 10pt;">Methods:</span></em></strong><span style="font-size: 10pt;"> Sixty-two ALL patients and 62 healthy sex-and age-matched controls were studied. After genotyping, the promoter region of the BAX and BCL-2 genes by RFLP-PCR method the patients were classified in nine prognostic groups, after that, the overall survival ratio of each score was compared with others pair-wise or between groups.</span></span></p> <p dir="ltr" style="text-align: justify;"><span style="font-family: times new roman;"><strong><em><span style="color: blue; font-size: 10pt;">Results:</span></em></strong><span style="font-size: 10pt;"> The frequencies of the AA, AC, CC alleles of the BCL-2 C-938A polymorphism in patient group were 33 (53.23%), 18 (29.03%), 11 (17.74%), and in the control group were 13 (21.0%), 27 (43.5%), 22 (35.5%), respectively (P=0.003). Also, the frequencies of AA, AG, GG alleles of the BAX G-248A SNP were 15 (24.2%), 24 (38.7%), 23 (37.1%) in ALL group and 13 (21.0%), 25 (40.3%), 24 (38.7%) (p>0.05) in the control group. The survival time estimation and ratio were significantly different between different SNPs in BCL-2 (P=0.002).</span></span></p> <p dir="ltr" style="text-align: justify;"><span style="font-family: times new roman;"><strong><em><span style="color: blue; font-size: 10pt;">Conclusion:</span></em></strong><span style="font-size: 10pt;"> </span><span style="font-size: 10pt;">These findings showed that the BCL-2 promoter region polymorphism is more reliable than BAX gene promoter polymorphism in any ALL scoring system. But the establishment of complete scoring system requires further more clinical and laboratory findings along with genetic polymorphisms is necessary</span></span></p> Acute Lymphoblastic Leukemia, BAX, BCL2, Prognostic Scoring, Survival, Single Nucleotide Polymorphism 105 113 http://caspjim.com/browse.php?a_code=A-10-351-1&slc_lang=en&sid=1 Mozhgan Moazami-Goudarzi mgn_moazami@yahoo.com 10031947532846005334 10031947532846005334 No Stem Cell Research Center, Tabriz University of Medical Science, Tabriz, Iran Majid Farshdousti-Hagh mt09143163667@gmail.com 10031947532846005335 10031947532846005335 No Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran Abbasali Hoseinpour-Feizi pourfeizia@yahoo.com 10031947532846005336 10031947532846005336 No Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran Mehdi Talebi mt09143163667@yahoo.com 10031947532846005337 10031947532846005337 Yes Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran Ali-Akbar Movassaghpour-Akbari movassaghpour@tbzmed.ac.ir 10031947532846005338 10031947532846005338 No Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran Karim Shams-Asanjan kshams@ibto.ir 10031947532846005339 10031947532846005339 No Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran Jamal Eyvazi-Ziyaee eyvazij@yahoo.com 10031947532846005340 10031947532846005340 No Hematology and Oncology Research center, Tabriz University of Medical Science, Tabriz, Iran Morteza Seifi 10031947532846005341 10031947532846005341 No Department of Medical Genetics, University of Alberta, Alberta, Canada